Cannabidiol zur Verbesserung der Genesung in frühen Stadien einer Schizophrenie

Zusammenfassung

Die Behandlung von Patienten mit schizophrenen Psychosen stellt trotz der Fortschritte der vergangenen Jahrzehnte immer noch eine große Herausforderung insbesondere im Hinblick auf die Genesung der Patienten dar. Obschon gerade die Akutsymptomatik mit den verfügbaren Antipsychotika verhältnismäßig gut zu behandeln ist, stellen deren eingeschränkte Wirksamkeit gegen Negativsymptomatik und kognitiven Einschränkungen und das Profil unerwünschter Wirkungen ein Problem im Hinblick auf die vollständige Wiederherstellung der sozialen und beruflichen Leistungsfähigkeit und Integration vieler Patienten dar. Im Rahmen des ESPRIT-Forschungsnetzwerkes führen wir daher eine klinische Prüfung von Cannabidiol als Zusatzmedikation bei post-akuten schizophrenen Psychosen in frühen Erkrankungsstadien durch. Hierbei werden die längerfristige Wirksamkeit und Verträglichkeit dieser Substanz geprüft, deren Wirkmechanismus die Modulation des Endocannabinoidsystems umfasst. Damit stellt Cannabidiol eine potentiell neue Wirkstoffklasse in der Behandlung von Psychosen dar, die die Genesung von Patienten hoffentlich zu verbessern hilft.

 

MissingLinkText

Summary

Despite recent advances, the treatment of schizophrenic psychoses remains a considerable challenge when remission is the goal. Although acute psychotic symptoms respond quite well to current antipsychotics, their limited effects on negative symptoms and cognitive decline as well as their side-effect profile are still problematic regarding full recovery of social and vocational performance and integration for a substantial number of patients. The ESPRIT research network is focussed on early stages of psychosis and will examine the therapeutic potential of cannabidol as an add-on treatment in post-acute schizophrenia. In this double blind randomized clinical trial, longer-term efficacy and safety of the compound will be investigated. Cannabidiol acts by modulating the function of the endocannabinoid system. Thereby, it represents a potentially new class of antipsychotic compounds, hopefully effective to improve recovery of schizophrenic patients.

 

MissingLinkText

Schlüsselwörter

Cannabidiol - Schizophrenie - Remission - Adjuvans

Keywords

Cannabidiol - schizophrenia - remission - add-on

 

 

MissingLinkText

Interessenkonflikt

FML ist Gesellschafter der curantis UG (haftungsbeschränkt) und hat Forschungsgelder der Acerus Pharmaceuticals, Kanada erhalten. Alle anderen Autoren erklären keine Interessenkonflikte.

• Literatur

• 1 Leweke FM, Odorfer TM, Bumb JM. Medical needs in the treatment of psychotic disorders. Handb Exp Pharmacol 2012; 212: 165-85.
• 2 Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S. et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110 (1–3): 103-10.
• 3 Mueller JK, Rohleder C, Leweke FM. What is the promise of nicotinergic compounds in schizophrenia treatment?. Future Medicinal Chemistry 2016; 08: 2008-12.
• 4 Rohleder C, Müller JK, Lange B, Leweke FM. Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence. Frontiers in Pharmacology. 2016 7(422).
• 5 Leweke FM, Mueller JK, Lange B, Rohleder C. Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry 2016; 79 (07) 604-12.
• 6 Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG. et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009; 23 (08) 979-83.
• 7 Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE. et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20 (05) 683-6.
• 8 Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56 (10) 485-6.
• 9 Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C. et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 02: e94.
• 10 Ryan D, Drysdale AJ, Pertwee RG, Platt B. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci 2007; 25 (07) 2093-102.
• 11 Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernandez-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007; 26 (04) 843-51.
• 12 Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I. et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134 (04) 845-52.
• 13 Müller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008; 08 (07) 1037-48.
• 14 Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 1996; 19 (08) 1109-11.
• 15 De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011; 163 (07) 1479-94.
• 16 Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L. et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem 2015; 290 (14) 8711-21.
• 17 Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008; 13 (02) 264-75.
• 18 O’Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007; 152 (05) 576-82.
• 19 McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R. et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry 2018; 175 (03) 225-231.
• 20 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13 (02) 261-76.
• 21 D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G. et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57 (06) 594-608.